There is no cure or effective treatment for the 10 million patients affected by Age-related Macular Degeneration (AMD) that result in visual impairment or blindness. Although there is no clinically approved treatment in the United States that would restore vision to the eye, some drugs, such as Lucentis, may be able to slow or improve vision loss. Other treatments include laser treatment or implantable telescopes. However, most treatment methods are mostly performed with patients with wet AMD. Consequently, there is a significant need for alternative therapeutic strategies. Most recently, cell transplantation has also been shown to rescue rod and cone photoreceptors and minimize the loss of behaviorally measured thresholds for up to 8 months of age in some cases. These transplanted therapeutic cells into the subretinal space of rodents and non-human primates have become a well-established method for evaluating potential treatments. These cells have been shown to survive throughout the course of the short-term study with no adverse effects on host retinal function using multifocal electroretinography (ERG). Specific information regarding cell survival, migration, and integration in the host is primarily derived from post-mortem histological assessments. The serial nature of this method requires large numbers of animals for these studies at multiple time points since there is currently no method for evaluating these efficacious cell-based therapies longitudinally in vivo. Consequently, the development of technology to visually track the transplanted cells survival and migration in vivo is of significant interest. Here, we develop cell-labeling agents to track these cells.